Economy News – Baghdad
The Samarra Medicines Company has announced a strategic initiative aimed at enhancing the supply of pharmaceutical preparations to governmental and health institutions. This initiative focuses particularly on the increased production of anti-allergic medications and treatments for chronic diseases.
The estimated cost for the company’s production plan for February 2025 is projected to surpass 3 billion and 25 million dinars. This budget is allocated to equip the Ministry of Health and the local market with a variety of pharmaceutical products, including pills, ointments, powders, and liquid forms.
Al-Nuaimi stated that the workforce in the production and support divisions has commenced the execution of the February production plan, which was developed in collaboration with the Iraqi Ministry of Health and a specialized marketing agency for the distribution of the company’s pharmaceutical offerings.
He elaborated that “the production plan may be subject to expansion depending on the availability of raw materials and other production inputs. The plan will also include the ramp-up of manufacturing for innovative medications that address various chronic conditions, in addition to respiratory drugs, cough suppressants, and pain relief formulations suitable for all age demographics.”
Al-Nuaimi emphasized that “the production schedule encompasses the manufacturing of pediatric medications for the local market, as well as powders designed to treat indigestion and urological issues.” He further noted that “the company intends to supply the local market with a diverse range of anti-fungal ointments and treatments for various dermatological conditions.”
To stay updated with the latest news, subscribe to our channel on Tilekram
